Certolizumab pegol + Placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cystitis, Interstitial

Conditions

Cystitis, Interstitial

Trial Timeline

Dec 15, 2015 → Jul 12, 2017

NCT ID

NCT02497976

About Certolizumab pegol + Placebo

Certolizumab pegol + Placebo is a phase 3 stage product being developed by UCB for Cystitis, Interstitial. The current trial status is completed. This product is registered under clinical trial identifier NCT02497976. Target conditions include Cystitis, Interstitial.

What happened to similar drugs?

2 of 4 similar drugs in Cystitis, Interstitial were approved

Approved (2) Terminated (2) Active (1)

✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved

✅RocuroniumMerckApproved

❌Mirabegron + PlaceboAstellas PharmaPhase 3

🔄moxifloxacinBayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04123795	Phase 3	Active	Jan 21, 2020	Aug 15, 2034	Moderate Chronic Plaque Psoriasis
NCT02497976	Phase 3	Completed	Dec 15, 2015	Jul 12, 2017	Cystitis, Interstitial
NCT01091220	Phase 1	Completed	Mar 1, 2010	Mar 1, 2011	Sperm Quality
NCT00674362	Phase 3	Completed	Jun 1, 2008	Dec 1, 2010	Rheumatoid Arthritis

Competing Products

19 competing products in Cystitis, Interstitial

See all competitors

Product	Company	Stage	Hype Score
Ferumoxytol + Gadobutrol	Lipella Pharmaceuticals	Phase 1	19
LP-10	Lipella Pharmaceuticals	Phase 2	25
LP-08 80mg + Normal saline + LP-08 20mg	Lipella Pharmaceuticals	Phase 2	25
ASP3652 + Placebo	Astellas Pharma	Phase 2	35
Mirabegron + Placebo	Astellas Pharma	Phase 3	32
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	42
Placebo + JNJ-42160443	Johnson & Johnson	Phase 2	27
Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg	Johnson & Johnson	Approved	35
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	35
Rocuronium	Merck	Approved	43
Cidofovir	Gilead Sciences	Pre-clinical	18
PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685	Pfizer	Phase 2	35
Tanezumab + Tanezumab + Tanezumab + Tanezumab	Pfizer	Phase 2	27
ERB-041	Pfizer	Pre-clinical	18
PF-04383119 + Placebo	Pfizer	Phase 2	35
moxifloxacin	Bayer	Phase 3	37
Cipro (Ciprofloxacin, BAYQ3939)	Bayer	Pre-clinical	23
IW-3300 rectal foam + Placebo	Ironwood Pharmaceuticals	Phase 2	21
MN-001 BID + MN-001 + Placebo	MediciNova	Phase 2	25